#Canada #Toronto #cancer detection #Geneseeq #CanScan

Geneseeq's Innovative Blood Test for Early Cancer Detection

Geneseeq Technology Inc. has recently gained significant attention in the medical community with the publication of its study results in the prestigious journal Nature Medicine. The company has developed a groundbreaking blood test, called CanScan®, which has shown remarkable accuracy in detecting early-stage cancers.

Introduction to CanScan®

Traditionally, cancer screening methods have relied heavily on invasive procedures and often focus on a single type of cancer. However, CanScan® offers a non-invasive alternative that evaluates multiple cancers simultaneously through a single blood draw. This innovation harnesses advanced artificial intelligence and whole-genome sequencing to examine circulating cell-free DNA (cfDNA) for subtle changes indicative of cancer.

Geneseeq’s proprietary MERCURY™ Technology enables the test to integrate various genomic, epigenomic, and fragmentomic features, allowing for the detection of cancer signals and predicting the tissue of origin accurately.

The DECIPHE-Omnia Study

The publication outlines results from the DECIPHE-Omnia study (Detecting Early Cancer by Inspecting ctDNA Features), which involved over 8,000 participants. This landmark clinical research program included phases such as test development, independent validation, and population screening of asymptomatic individuals aged 45-75 in the JINLING cohort.

Notably, interim results from over 3,700 participants revealed that:

• - Specificity: 98.1%
• - Sensitivity: 53.5% across all detected cancers (with 62.1% for targeted cancer types)
• - Early-stage Detection: 93% of confirmed cancer cases were classified as Stage 0, I, or II
• - Positive Predictive Value (PPV): 25%, tenfold higher than standard screening procedures
• - Detection of Missed Cancers: CanScan® identified 53.3% of cancers overlooked by standard methods

These statistics demonstrate how CanScan® effectively addresses gaps left by traditional screening practices and can significantly impact cancer outcomes.

Looking Forward: The Future of Cancer Screening

Dr. Yang Shao, CEO of Geneseeq, emphasized the importance of this study in bringing routine multi-cancer screening closer to reality. With the completion of the JINLING cohort’s enrollment of 15,000 participants, ongoing analysis is set to provide further insights into the real-world applicability of CanScan® for early cancer detection at a population level.

About Geneseeq Technology Inc.

Based in Canada and China, Geneseeq is a trailblazer in precision oncology, focusing on next-generation sequencing technologies that transform cancer detection, diagnosis, and treatment. Their extensive portfolio includes comprehensive genomic profiling, cancer-specific panels, and minimally invasive monitoring solutions. The company has achieved several vital milestones, including receiving Breakthrough Device Designation from the FDA for CanScan®, showcasing its commitment to advancing cancer care.

Conclusion

Geneseeq's innovative approach to cancer detection with the CanScan® blood test raises hopes for a future where early diagnosis is more accessible and less invasive. As the landscape of healthcare continues to evolve, solutions like CanScan® could redefine how we understand, screen for, and treat cancer, ultimately saving lives through earlier and more accurate diagnosis.